| Predicted Trait | |
| Reported Trait | Prostate cancer |
| Mapped Trait(s) | prostate carcinoma (EFO_0001663) |
| Score Construction | |
| PGS Name | PRS_PrCa |
| Development Method | |
| Name | Genome-wide significant variants |
| Parameters | Risk was normalized to population average (see Methods 2.3). Includes proxy variants |
| Variants | |
| Original Genome Build | GRCh37 |
| Number of Variants | 72 |
| Effect Weight Type | log(OR) |
| PGS Source | |
| PGS Catalog Publication (PGP) ID | PGP000113 |
| Citation (link to publication) | Black MH et al. Prostate (2020) |
| Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
|---|---|---|---|
Europe PMC: 19767752 |
[
|
European | ProtecT, UKGPCS |
GWAS Catalog: GCST000017 Europe PMC: 17401363 |
2,329 individuals | European | NR |
| — | [ ,
100.0 % Male samples |
European | 37 cohorts
|
GWAS Catalog: GCST001942 Europe PMC: 23535732 |
22,548 individuals | European | NR |
GWAS Catalog: GCST002606 Europe PMC: 25217961 |
2,080 individuals | Hispanic or Latin American | NR |
GWAS Catalog: GCST002606 Europe PMC: 25217961 |
6,954 individuals | East Asian | NR |
GWAS Catalog: GCST002606 Europe PMC: 25217961 |
10,463 individuals | Sub-Saharan African, African American or Afro-Caribbean | NR |
GWAS Catalog: GCST002606 Europe PMC: 25217961 |
67,543 individuals | European | NR |
GWAS Catalog: GCST001147 Europe PMC: 21743057 |
7,240 individuals | European | NR |
GWAS Catalog: GCST000019 Europe PMC: 17401366 |
4,517 individuals | European | ICR, IGD, deCODE |
GWAS Catalog: GCST000488 Europe PMC: 19767753 |
3,748 individuals | European | ProtecT, UKGPCS |
GWAS Catalog: GCST002944 Europe PMC: 26034056 |
3,226 individuals | East Asian | CMHS, GERA, ProHealth, RPGEH |
GWAS Catalog: GCST002944 Europe PMC: 26034056 |
2,251 individuals | African American or Afro-Caribbean | CMHS, GERA, ProHealth, RPGEH |
GWAS Catalog: GCST002944 Europe PMC: 26034056 |
3,629 individuals | Hispanic or Latin American | CMHS, GERA, ProHealth, RPGEH |
GWAS Catalog: GCST002944 Europe PMC: 26034056 |
37,272 individuals | European | CMHS, GERA, ProHealth, RPGEH |
GWAS Catalog: GCST000153 Europe PMC: 18264098 |
23,226 individuals | European | ICR, IGD, deCODE |
GWAS Catalog: GCST000152 Europe PMC: 18264097 |
3,748 individuals | European | ProtecT, UKGPCS |
GWAS Catalog: GCST000489 Europe PMC: 19767754 |
37,350 individuals | European | ICR, IGD, deCODE |
GWAS Catalog: GCST000154 Europe PMC: 18264096 |
2,329 individuals | European | PLCO |
|
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
|---|---|---|---|---|---|---|---|---|
| PPM000987 | PSS000502| European Ancestry| 1,039 individuals |
PGP000113 | Black MH et al. Prostate (2020) |
Reported Trait: Prostate cancer in men with a family history of prostate cancer | OR: 1.9 [1.53, 2.4] | — | — | Age | — |
| PPM000986 | PSS000501| European Ancestry| 3,891 individuals |
PGP000113 | Black MH et al. Prostate (2020) |
Reported Trait: Prostate cancer | — | AUROC: 0.64 | — | Age | — |
| PPM000985 | PSS000501| European Ancestry| 3,891 individuals |
PGP000113 | Black MH et al. Prostate (2020) |
Reported Trait: Prostate cancer | OR: 1.72 [1.59, 1.88] | AUROC: 0.64 [0.62, 0.66] | — | — | — |
| PPM000988 | PSS000503| European Ancestry| 2,305 individuals |
PGP000113 | Black MH et al. Prostate (2020) |
Reported Trait: Prostate cancer in men with no family history of prostate cancer | OR: 1.65 [1.49, 1.84] | — | — | Age | — |
|
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
|---|---|---|---|---|---|---|---|---|
| PSS000501 | Cases: Male, self-reported European ancestry, greater or equal to 18 years of age at prostate cancer diagnosis. JHH cases were patients undergoing radical prostatectomy for the treatment of clinically localized PrCa in 2002 to 2015 and were included if disease was organ‐confined and Gleason score ≤6 or ≥8, as determined upon pathological evaluation of the prostatectomy specimen. Only the high‐ and low‐grade PrCa JHH cases were included because they were previously curated to assess the association of RPVs in cancer susceptibility genes with PrCa. JHH controls were included if they self repored with European American ancestry, had a normal digital rectal examination, PSA level less than 4.0 ng/mL and were older than 55 years. AG cases and controls were men referred for multigene panel testing in 2017 to 2019. Among AG cases, 104 patients had Gleason ≥8, and 59 patients had Gleason ≤6, and 230 patients had no pathology information. AG controls were unaffected with prostate cancer at the time of testing. NSGI controls had a minimum of 1 year clincal history available in the EHR and were exlucded if any ICD9/10 diagnosis of cancer was present at any time in the EHR. Men who tested positive for RPVs in any prostate cancer susceptibility gene were exlcuded from further analysis. | — | [ ,
100.0 % Male samples |
— | European | — | AG, JHH, NSGHI | — |
| PSS000502 | Cases: Male, self-reported European ancestry, greater or equal to 18 years of age at prostate cancer diagnosis. JHH cases were patients undergoing radical prostatectomy for the treatment of clinically localized PrCa in 2002 to 2015 and were included if disease was organ‐confined and Gleason score ≤6 or ≥8, as determined upon pathological evaluation of the prostatectomy specimen. Only the high‐ and low‐grade PrCa JHH cases were included because they were previously curated to assess the association of RPVs in cancer susceptibility genes with PrCa. JHH controls were included if they self repored with European American ancestry, had a normal digital rectal examination, PSA level less than 4.0 ng/mL and were older than 55 years. AG cases and controls were men referred for multigene panel testing in 2017 to 2019. Among AG cases, 104 patients had Gleason ≥8, and 59 patients had Gleason ≤6, and 230 patients had no pathology information. AG controls were unaffected with prostate cancer at the time of testing. | — | [ ,
100.0 % Male samples |
— | European | — | AG, JHH | — |
| PSS000503 | Cases: Male, self-reported European ancestry, greater or equal to 18 years of age at prostate cancer diagnosis. JHH cases were patients undergoing radical prostatectomy for the treatment of clinically localized PrCa in 2002 to 2015 and were included if disease was organ‐confined and Gleason score ≤6 or ≥8, as determined upon pathological evaluation of the prostatectomy specimen. Only the high‐ and low‐grade PrCa JHH cases were included because they were previously curated to assess the association of RPVs in cancer susceptibility genes with PrCa. JHH controls were included if they self repored with European American ancestry, had a normal digital rectal examination, PSA level less than 4.0 ng/mL and were older than 55 years. AG cases and controls were men referred for multigene panel testing in 2017 to 2019. Among AG cases, 104 patients had Gleason ≥8, and 59 patients had Gleason ≤6, and 230 patients had no pathology information. AG controls were unaffected with prostate cancer at the time of testing. | — | [ ,
100.0 % Male samples |
— | European | — | AG, JHH | — |